Staff Contact: Sarah Willson
The DEA and HHS recently extended controlled substance telemedicine prescribing flexibilities through Dec. 31, 2024. This is the second temporary extension after issuing temporary rules in March 2023. MHA will continue to monitor and share additional details as they become available.